Table 2.
Patient characteristics and outcomes in the discovery (n = 110) and validation (n = 94) cohorts: validation cohort
| 1-y overall survival | 1-y relapse | ||||
|---|---|---|---|---|---|
| n | Probability (%) | HR (95%CI) (risk of death) | Cumulative incidence (%) | HR (95%CI) (risk of relapse) | |
| Age* | P = .09 | P = .35 | |||
| ≤40 y | 44 | 55.0 | 1 | 21.1 | 1 |
| >40 y | 50 | 31.1 | 1.27 (0.72-1.90) | 25.5 | 1.02 (0.45-2.30) |
| Sex | P = .61 | P = .19 | |||
| Male | 54 | 40.0 | 1 | 19.5 | 1 |
| Female | 40 | 43.7 | 0.78 (.45-1.37) | 27.3 | 1.67 (0.77-3.61) |
| Diagnosis | P = .51 | P = .23 | |||
| AML | 39 | 43.6 | 1 | 33.3 | 1 |
| Acute lymphoblastic leukemia | 25 | 40.0 | 0.96 (0.50-18.5) | 40.1 | 1.27 (0.53-2.78) |
| Myelodysplastic syndromes | 5 | 80.0 | 0.26 (0.21-1.81) | 20.0 | 0.55 (0.07-4.20) |
| Lymphoproliferative disorder† | 16 | 37.5 | 1.19 (0.57-2.53) | 16.2 | 0.14 (0.2-1.18) |
| Chronic myeloid leukemia | 9 | 56.6 | 0.62 (.21-1.81) | 12.5 | 0.30 (0.04-2.32) |
| Disease status at transplant | P = .04 | P = .02 | |||
| Complete remission | 52 | 48.9 | 1 | 17.8 | 1 |
| Refractory/relapsed disease | 42 | 34.2 | 1.47 (1.09-2.56) | 33.2 | 1.84 (1.13-4.22) |
| Conditioning regimen | P = .87 | P = .65 | |||
| Myeloablative | 73 | 40.9 | 1 | 25.1 | 1 |
| Nonmyeloablative | 21 | 47.4 | 1.09 (0.63-1.71) | 17.6 | 0.85 (0.42-1.88) |
| Graft | P = .73 | P = .73 | |||
| Double cord | 88 | 40.5 | 1 | 31.9 | 1 |
| Single cord | 6 | 66.7 | 0.91 (0.50-1.68) | 16.7 | 0.84 (0.23-1.86) |
| CMV status‡ | P = .78 | P = .44 | |||
| Seronegative | 16 | 42.9 | 1 | 43.2 | 1 |
| Seropositive | 76 | 42.3 | 0.99 (0.77-1.36) | 29.1 | 0.65 (0.20-1.91) |
| HLA match between recipient and dominant CB unit§ | P = .11 | P = .26 | |||
| 7-8/8 | 10 | 75.1 | 1 | 20.1 | 1 |
| 5-6/8 | 31 | 36.8 | 1.61 (0.96-4.71) | 36.8 | 1.4 (0.84-2.33) |
| ≤4/8 | 43 | 38.2 | 1.79 (0.91-3.54) | 18.6 | 0.99 (0.70-1.24) |
| Total mononuclear cells infused|| | P = .91 | P = .73 | |||
| ≤3.8 × 108/kg | 42.9 | 1 | 26.8 | 1 | |
| >3.8 × 108/kg | 39.0 | 0.97 (0.55-1.70) | 24.4 | 0.862 (0.37-2.03) | |
| Patient HLA C group¶,# | P = .002 | P < .001 | |||
| C1/C1 | 38 | 50.0 | 1 | 22.2 | 1 |
| C1/C2 | 40 | 52.0 | 0.91 (0.47-1.76) | 18.1 | 0.83 (0.30-2.34) |
| C2/C2 | 16 | 12.5 | 2.73 (1.30-5.75) | 68.7 | 5.34 (1.96-14.50) |
| Patient HLA C group | P < .001 | P < .001 | |||
| C1/x | 78 | 51.3 | 1 | 19.5 | 1 |
| C2/C2 | 16 | 12.5 | 2.90 (1.56-5.38) | 68.7 | 5.98 (2.73-13.10) |
| Patients receiving CB grafts with the combined HLA-C1-KIR2DL2/L3/S2 genotype | P = .07 | P = .05 | |||
| Yes | 37 | 56.8 | 1 | 16.2 | 1 |
| No | 57 | 36.8 | 1.70 (0.94-3.07) | 35.7 | 2.38 (0.96-5.94) |
| HLA-C1/x patients receiving CB grafts with the combined HLA-C1-KIR2DL2/L3/S2 genotype | P = .02 | P = .01 | |||
| Yes | 31 | 67.7 | 1 | 6.5 | 1 |
| No | 47 | 40.4 | 2.33 (1.13-4.81) | 28.3 | 5.02 (1.13-22.26) |
| HLA match between recipient and dominant CB unit§ | P = .11 | P = .26 | |||
| 7-8/8 | 10 | 75.1 | 1 | 20.1 | 1 |
| 5-6/8 | 31 | 36.8 | 1.61 (0.96-4.71) | 36.8 | 1.4 (0.84-2.33) |
| ≤4/8 | 43 | 38.2 | 1.79 (0.91-3.54) | 18.6 | 0.99 (0.70-1.24) |
| Patients received CB grafts with the combined HLA-C2-KIR2DL1/S1 genotype | P = .54 | P = .20 | |||
| Yes | 35 | 46.6 | 1 | 23.1 | 1 |
| No | 59 | 41.7 | 1.19 (0.68-2.07) | 34.1 | 1.31 (0.76-2.01) |
Median age was 41.0 y (range, 1-73).
Five patients had chronic lymphocytic leukemia; 5 patients had Hodgkin disease, and 6 patients had non-Hodgkin lymphoma.
Two patients had missing data.
The identity of the dominant CB unit could not be ascertained in 10 cases.
The median value for the total of nucleated cells infused was 3.8 × 108/kg (range, 1.5 × 108/kg to 34.2 × 108/kg).
The P values for the comparisons of outcomes in C1/C1 vs C2/C2 patients were P = .007 for OS and P < .001 for cumulative incidence of progression.
The P values for the comparisons of outcomes in C1/C2 vs C2/C2 patients were P = .001 for OS and P < .001 for cumulative incidence of progression.